Early relapse predicts poor outcomes in patients with mantle cell lymphoma
ORLANDO — Patients with mantle cell lymphoma who relapse within 6 months of frontline therapy experienced poor outcomes with current salvage therapies, according to results presented at ASH Annual Meeting and Exposition. “Patients with very early relapse of mantle cell lymphoma experience poor outcomes with standard therapies, supporting the development of new treatment